Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000783%Not Available
Food intolerance14.02.01.005--Not Available
Gastrointestinal obstruction07.13.01.0050.000627%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Immunosuppression10.03.02.0010.002663%Not Available
Lung neoplasm22.08.01.006; 16.19.04.0010.000313%Not Available
Large intestinal obstruction07.13.03.0030.000470%
Renal mass20.01.02.0070.000313%Not Available
Venoocclusive disease24.03.02.016--Not Available
Microangiopathy24.03.02.0210.000313%Not Available
Renal impairment20.01.03.0100.002506%Not Available
Sinus disorder22.04.06.002--
Unevaluable event08.01.03.051--Not Available
Bowel movement irregularity07.02.03.003--Not Available
Hypophagia07.01.06.010; 19.09.01.004; 14.03.01.0060.001097%Not Available
Gastrointestinal inflammation07.08.03.0070.005859%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.000313%Not Available
Infusion site extravasation12.07.05.008; 08.02.05.007--
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.001410%Not Available
Bone marrow failure01.03.03.0050.002976%
Bone loss15.02.04.020--Not Available
Pharyngeal inflammation22.04.05.0080.000313%
Injection site papule23.03.03.045; 12.07.03.031; 08.02.03.0310.001222%Not Available
Cytopenia01.03.03.0120.000470%Not Available
Thyroid cancer16.24.03.001; 05.02.05.001--Not Available
Treatment failure08.06.01.0170.004950%Not Available
Hepatosplenic T-cell lymphoma16.17.01.001; 01.11.01.0010.001253%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000470%Not Available
Organising pneumonia22.01.02.0080.000470%Not Available
Low birth weight baby18.04.02.0030.000940%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene